After sharing word that it would be prioritizing artificial intelligence to aid discovery work, Takeda Pharmaceuticals has ...
Pharmaceutical Technology on MSN
Takeda and Iambic announce $1.7bn deal to advance small molecule programmes
The partnership aims to advance high-priority small molecule programmes using Iambic’s AI models and wet lab capabilities.
FDA Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton as a Potential First-in-Class Therapy ...
Quarter after quarter for the past year, Takeda’s revenues have been bogged down by generic impacts to its stalwart ADHD med Vyvanse. | The gap between Vyvanse generic sales declines and growth from ...
Takeda’s real estate downsize will add to the region’s growing office sublease market. A January 2026 CBRE report on the ...
By Kamal Choudhury Feb 9 (Reuters) - Privately held Iambic said on Monday it has entered a multi-year partnership worth more ...
Takeda Pharmaceutical is quietly turning into one of Cambridge’s biggest sublandlords, marketing roughly 449,000 square feet of lab and office space as it prepares to centralize research and ...
Takeda will reorganize its executive leadership team and business structure as it seeks to accelerate growth and ...
The US Food and Drug Administration (FDA) has accepted Takeda’s New Drug Application (NDA) and granted Priority Review for ...
The pharmaceutical company plans to sublease space at BioMed's 35 Landsdowne St., 40 Landsdowne St. and 300 Massachusetts Ave. in Cambridge.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results